TipRanks
Go Ultimate55% OFF

Ocugen (OCGN) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Ocu410Dry Age-Related Macular DegenerationPhase IIIRecruitingPhase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMDAug 13, 2026―
Sub-Retinal Administration Of Ocu400-301Retinitis PigmentosaPhase IIIActive Not RecruitingA Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis PigmentosaApr 09, 2024
Ocu410Geographic Atrophyphase1AndPhase2Active Not RecruitingStudy to Assess the Safety and Efficacy of OCU410 for Geographic AtrophyJun 30, 2023―
Ocu410stStargardt Diseasephase2AndPhase3Active Not RecruitingA Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt DiseaseJun 30, 2023
Ocu200Diabetic Macular Edema, Center Involved Diabetic Macular EdemaPhase IRecruitingPhase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)Mar 27, 2023
Ocu400 Low Dose, Ocu400 Med Dose, Ocu400 High Dose, Ocu400 Second Eye DosingRetinitis Pigmentosa, Leber Congenital Amaurosisphase1AndPhase2Active Not RecruitingStudy to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital AmaurosisNov 16, 2021―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Ocugen Inc (OCGN) have in its pipeline
Ocugen OCGN is currently developing the following drugs: Ocu410, Sub-Retinal Administration Of Ocu400-301, Ocu410st, Ocu200, Ocu400 Low Dose, Ocu400 Med Dose, Ocu400 High Dose, Ocu400 Second Eye Dosing. These drug candidates are in various stages of clinical development as the company works toward FDA approval.